ARDX

Ardelyx, Inc.

6.41 USD
-0.08 (-1.23%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Ardelyx, Inc. stock is down -18.34% since 30 days ago. The next earnings date is Jul 31, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 40% of the previous 10 June’s closed higher than May. In the last 10 Unusual Options Trades, there were 9 CALLs, 1 PUT. 100% of analysts rate it a buy.

Options Flow Last 10
Date & Time Expiration Date Strike Price Trade Type Size Open Interest
29 May 13:50 17 Jan, 2025 3.50 CALL 100 1394
29 May 14:02 17 Jan, 2025 3.50 CALL 90 1394
29 May 18:46 17 Jan, 2025 3.50 CALL 100 1394
29 May 18:47 17 Jan, 2025 3.50 CALL 100 1394
29 May 18:49 17 Jan, 2025 3.50 CALL 86 1394
31 May 19:43 17 Jan, 2025 3.50 CALL 250 1801
03 Jun 13:44 17 Jan, 2025 3.50 CALL 80 2051
10 Jun 18:40 16 Jan, 2026 4.50 CALL 95 973
10 Jun 19:59 17 Jan, 2025 5.00 CALL 146 4220
13 Jun 19:28 19 Jul, 2024 7.00 PUT 500 2645

About Ardelyx, Inc.

Ardelyx, Inc. discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation. It is also developing RDX013, a potassium secretagogue, for the. treatment of elevated serum potassium, or hyperkalemia, among certain patients with kidney and/or heart disease.

  • Piper Sandler
    Fri May 24, 12:27
    buy
    confirm
  • Wedbush
    Fri May 24, 10:07
    buy
    confirm